Last reviewed · How we verify
Influenza Vaccine, recombinant Hemagglutinin
Influenza Vaccine, recombinant Hemagglutinin is a Biologic drug developed by Protein Sciences Corporation. It is currently in Phase 2 development. Also known as: FluBlok, rHA, rHA0, recombinant hemagglutinin.
At a glance
| Generic name | Influenza Vaccine, recombinant Hemagglutinin |
|---|---|
| Also known as | FluBlok, rHA, rHA0, recombinant hemagglutinin |
| Sponsor | Protein Sciences Corporation |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age (PHASE3)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- Open-Label Influenza Vaccine Evaluation (NA)
- The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study (PHASE4)
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Immunogenicity Trial of 3 Influenza Vaccines (PHASE3)
- Flublok or Fluzone With Advax-CpG55.2 or AF03 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza Vaccine, recombinant Hemagglutinin CI brief — competitive landscape report
- Influenza Vaccine, recombinant Hemagglutinin updates RSS · CI watch RSS
- Protein Sciences Corporation portfolio CI
Frequently asked questions about Influenza Vaccine, recombinant Hemagglutinin
What is Influenza Vaccine, recombinant Hemagglutinin?
Influenza Vaccine, recombinant Hemagglutinin is a Biologic drug developed by Protein Sciences Corporation.
Who makes Influenza Vaccine, recombinant Hemagglutinin?
Influenza Vaccine, recombinant Hemagglutinin is developed by Protein Sciences Corporation (see full Protein Sciences Corporation pipeline at /company/protein-sciences-corporation).
Is Influenza Vaccine, recombinant Hemagglutinin also known as anything else?
Influenza Vaccine, recombinant Hemagglutinin is also known as FluBlok, rHA, rHA0, recombinant hemagglutinin.
What development phase is Influenza Vaccine, recombinant Hemagglutinin in?
Influenza Vaccine, recombinant Hemagglutinin is in Phase 2.
Related
- Manufacturer: Protein Sciences Corporation — full pipeline
- Also known as: FluBlok, rHA, rHA0, recombinant hemagglutinin
- Compare: Influenza Vaccine, recombinant Hemagglutinin vs similar drugs
- Pricing: Influenza Vaccine, recombinant Hemagglutinin cost, discount & access